Compass Therapeutics (NASDAQ: CMPX) shares Q3 and nine-month 2025 results via 8-K

Rhea-AI Filing Summary

Compass Therapeutics, Inc. filed a current report to share that it has released its financial results for the quarter and nine months ended September 30, 2025. The company reported these results via a press release dated November 5, 2025, which is attached to the report as an exhibit and incorporated by reference. The filing is focused on making this earnings information available to the market and does not itself detail the specific revenue, profit, or cash figures.

False000173802100017380212025-11-052025-11-05iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  November 5, 2025

_______________________________

Compass Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Delaware	001-39696	82-4876496
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

80 Guest Street, Suite 601

Boston, Massachusetts 02135

(Address of Principal Executive Offices) (Zip Code)

(617) 500-8099

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	CMPX	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 5, 2025, Compass Therapeutics, Inc. issued a press release announcing financial results for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits      

Exhibit No.		Exhibit
99.1		Press Release dated November 5, 2025 (furnished pursuant to Item 2.02)
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Compass Therapeutics, Inc.
Date: November 5, 2025	By:	/s/ Neil Lerner
		Neil Lerner
		Chief Accounting Officer

FAQ

What did Compass Therapeutics, Inc. (CMPX) report in this 8-K filing?

Compass Therapeutics, Inc. reported that it issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.

Which period do the Compass Therapeutics (CMPX) results in this filing cover?

The results discussed relate to the quarter and nine months ended September 30, 2025, as stated in the description of the attached press release.

Where can investors find the detailed financial results for Compass Therapeutics (CMPX)?

The detailed financial results are contained in the press release dated November 5, 2025, which is furnished as Exhibit 99.1 to the report and incorporated by reference.

Does this Compass Therapeutics (CMPX) filing include full financial statements?

The report states that a press release with financial results is furnished as an exhibit. The body of the report itself does not present full financial statements.

What exhibit is included with this Compass Therapeutics (CMPX) 8-K?

The filing includes Exhibit 99.1, a press release dated November 5, 2025, announcing financial results, and Exhibit 104, the cover page formatted in Inline XBRL.

Who signed this Compass Therapeutics (CMPX) 8-K report?

The report was signed on behalf of Compass Therapeutics, Inc. by Neil Lerner, who is identified as the Chief Accounting Officer.